Perspective on model‐informed drug development by Lawrence J. Lesko

Connect to this object online.

Quantitative Systems Pharmacology Model-Based Predictions of Clinical Endpoints to Optimize Warfarin and Rivaroxaban Anti-Thrombosis Therapy by Sonja Hartmann, Konstantinos Biliouris, Lawrence J. Lesko, Ulrike Nowak-Göttl, Mirjam N. Trame

Connect to this object online.

Advancing drug safety science by integrating molecular knowledge with post‐marketing adverse event reports by Theodoros G. Soldatos, Sarah Kim, Stephan Schmidt, Lawrence J. Lesko, David B. Jackson

Connect to this object online.

Application of a patient‐centered reverse translational systems‐based approach to understand mechanisms of an adverse drug reaction of immune checkpoint inhibitors by Sarah Kim, Gezim Lahu, Majid Vakilynejad, Theodoros G. Soldatos, David B. Jackson, Lawrence J. Lesko, Mirjam N. Trame

Connect to this object online.

A case study of a patient‐centered reverse translational systems‐based approach to understand adverse event profiles in drug development by Sarah Kim, Gezim Lahu, Majid Vakilynejad, Theodoros G. Soldatos, David B. Jackson, Lawrence J. Lesko, Mirjam N. Trame

Connect to this object online.

Physiologically‐based pharmacokinetics modeling to investigate formulation factors influencing the generic substitution of dabigatran etexilate by Nashid Farhan, Rodrigo Cristofoletti, Sumit Basu, Sarah Kim, Karthik Lingineni, Sibo Jiang, Joshua D. Brown, Lanyan (Lucy), Lawrence J. Lesko, Stephan Schmidt

Connect to this object online.

A Semi‐Mechanistic Population Pharmacokinetic Model of Nusinersen: An Antisense Oligonucleotide for the Treatment of Spinal Muscular Atrophy by Konstantinos Biliouris, Puneet Gaitonde, Wei Yin, Daniel A. Norris, Yanfeng Wang, Scott Henry, Robert Fey, Ivan Nestorov, Stephan Schmidt, Mark Rogge, Lawrence J. Lesko, Mirjam N. Trame

Connect to this object online.